

Crizotinib

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Crizotinib

ATC codes

[L01ED01](#)

Medicine type

Chemical agent

EML status history

Application rejected in 2017 ([TRS 1006](#)) for [Other specified malignant neoplasms of bronchus or lung](#)

Application rejected in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-positive](#)

Wikipedia

[Crizotinib](#)

DrugBank

[Crizotinib](#)

Recommendations

Section

Targeted therapies

- Oral > Solid: 200 mg; 250 mg
- Oral > Solid > capsule: 200 mg; 250 mg

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Anaplastic large cell lymphoma, ALK-positive](#)